100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AR078110
Award Date
9/10/20
Completion Date
8/31/22
Dollars Obligated
$250K
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Awardee
Signablok, Inc. (JM5UN38YM1H7)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Update #1
Update #2
TREM-1 INHIBITOR FOR THE TREATMENT OF SCLERODERMA
Posted 9/10/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
TREM-1 INHIBITOR FOR THE TREATMENT OF SCLERODERMA - PROJECT SUMMARY/ABSTRACT SCLERODERMA THAT INCLUDES LOCALIZED SCLERODERMA (LS) AND SYSTEMIC SCLEROSIS (SSC) IS A RARE BUT DEVASTATING AUTOIMMUNE DISORDER. CURRENT THERAPIES ALL HAVE SIDE EFFECTS, ARE LIMITED AND ASSOCIATE WITH 10 YEAR SURVIVAL OF 55%, SHOWING THE NEED FOR NOVEL APPROACHES. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A NEW MECHANISM-BASED, EFFICIENT AND WELL TOLERABLE SCLERODERMA THERAPY. TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1), AN INFLAMMATION AMPLIFIER, CONTRIBUTES TO THE DEVELOPMENT OF FIBROSIS IN SSC. IN PATIENTS, NUMBER OF ACTIVATED MACROPHAGES IN THE FIBROTIC AREAS IS INCREASED AND ASSOCIATES WITH FIBROSIS SEVERITY. ACTIVATION OF TREM-1 LEADS TO OVERPRODUCTION OF MCP- 1/CCL2 AND M-CSF/CSF-1, RESULTING IN MACROPHAGE RECRUITMENT TO AN INJURED AREA AND THE SCLEROTIC LESION FORMATION IN RATS WITH SCLERODERMA. IN ANIMAL MODELS, TREM-1 BLOCKADE INHIBITS INFLAMMATION AND AMELIORATES A VARIETY OF AUTOIMMUNE DISEASES. THE HYPOTHESIS OF THE "PROOF-OF-CONCEPT" PHASE I IS THAT TREM-1 BLOCKADE CAN PREVENT AND TREAT SCLERODERMA. CURRENT TREM-1 INHIBITORS ALL ATTEMPT TO BLOCK BINDING OF TREM-1 TO ITS STILL UNCERTAIN LIGAND(S). TO MINIMIZE RISK OF FAILURE IN CLINICAL DEVELOPMENT, WE DEVELOPED A FIRST-IN-CLASS LIGAND-INDEPENDENT TREM-1 INHIBITORY PEPTIDE GF9 THAT IS WELL-TOLERATED AND CAN BE FORMULATED INTO SIGNABLOK'S LONG HALF-LIFE MACROPHAGE-SPECIFIC LIPOPEPTIDE COMPLEXES (LPC) TO IMPROVE ITS HALF-LIFE AND TARGETING TO THE INFLAMMATION AREAS. THE MAJOR GOAL OF THE PHASE I STUDY IS TO SHOW THAT TREM-1 BLOCKADE BY GF9-LPC ALLEVIATES THE DISEASE IN A BLEOMYCIN (BLM)-INDUCED MOUSE MODEL OF SCLERODERMA. PHASE I SPECIFIC AIMS ARE TO: 1) OPTIMIZE TREM-1 INHIBITORY COMPOSITIONS FOR THEIR FUNCTIONALITY IN VITRO AND PHARMACOKINETICS IN VIVO AND SELECT THE LEAD, 2) TEST TWO DOSES OF THE LEAD SELECTED IN A BLM-INDUCED MOUSE MODEL OF SCLERODERMA. WE WILL GENERATE, OPTIMIZE AND SELECT THE LEAD BASED UPON ITS FUNCTIONALITY IN VITRO AND ITS PK PROFILE IN VIVO. WE WILL TEST TWO DOSES OF THE LEAD FOR ITS ABILITY TO PREVENT AND TREAT LUNG, HEART, MUSCLE AND SKIN FIBROSIS IN A MOUSE MODEL OF MULTIORGAN FIBROSIS IN VIVO. HISTOLOGY/IHC STUDIES WILL BE PERFORMED. SERUM AND TISSUE MCP-1, CSF-1, VEGF, TGFSS, TNFA, IL-6, AND IL-1SS WILL BE ANALYZED. IT IS ANTICIPATED THAT THE PHASE I STUDY WILL IDENTIFY A NOVEL, FIRST-IN-CLASS, WELL TOLERABLE AGENT AS A POWERFUL PLATFORM FOR DEVELOPMENT OF AN EFFECTIVE AND WELL-TOLERABLE SYSTEMIC SCLERODERMA THERAPY, THEREBY IMPROVING TREATMENT AND SURVIVAL OF PATIENTS. ITS ANTICIPATED SAFETY IS SUPPORTED BY GOOD TOLERABILITY OF SIGNABLOK'S GF9-BASED FORMULATIONS BY LONG TERM-TREATED MICE. PROTOTYPES OF SIGNABLOK'S LPC ARE WELL TOLERATED IN HUMANS. TREM-1 BLOCKADE BY SIGNABLOK COMPETITOR'S INHIBITORY PEPTIDE LR12 (INOTREM, FRANCE) WAS SAFE IN HEALTHY AND SEPTIC SUBJECTS. IF SUCCESSFUL, PHASE I WILL BE FOLLOWED IN PHASE II BY TOXICOLOGY, ADME, PHARMACOLOGY AND CMC STUDIES, FILING AN IND AND SUBSEQUENT EVALUATION IN HUMANS.
$0
4/24/23
Not listed
TREM-1 INHIBITOR FOR THE TREATMENT OF SCLERODERMA - PROJECT SUMMARY/ABSTRACT SCLERODERMA THAT INCLUDES LOCALIZED SCLERODERMA (LS) AND SYSTEMIC SCLEROSIS (SSC) IS A RARE BUT DEVASTATING AUTOIMMUNE DISORDER. CURRENT THERAPIES ALL HAVE SIDE EFFECTS, ARE LIMITED AND ASSOCIATE WITH 10 YEAR SURVIVAL OF 55%, SHOWING THE NEED FOR NOVEL APPROACHES. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A NEW MECHANISM-BASED, EFFICIENT AND WELL TOLERABLE SCLERODERMA THERAPY. TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1), AN INFLAMMATION AMPLIFIER, CONTRIBUTES TO THE DEVELOPMENT OF FIBROSIS IN SSC. IN PATIENTS, NUMBER OF ACTIVATED MACROPHAGES IN THE FIBROTIC AREAS IS INCREASED AND ASSOCIATES WITH FIBROSIS SEVERITY. ACTIVATION OF TREM-1 LEADS TO OVERPRODUCTION OF MCP- 1/CCL2 AND M-CSF/CSF-1, RESULTING IN MACROPHAGE RECRUITMENT TO AN INJURED AREA AND THE SCLEROTIC LESION FORMATION IN RATS WITH SCLERODERMA. IN ANIMAL MODELS, TREM-1 BLOCKADE INHIBITS INFLAMMATION AND AMELIORATES A VARIETY OF AUTOIMMUNE DISEASES. THE HYPOTHESIS OF THE "PROOF-OF-CONCEPT" PHASE I IS THAT TREM-1 BLOCKADE CAN PREVENT AND TREAT SCLERODERMA. CURRENT TREM-1 INHIBITORS ALL ATTEMPT TO BLOCK BINDING OF TREM-1 TO ITS STILL UNCERTAIN LIGAND(S). TO MINIMIZE RISK OF FAILURE IN CLINICAL DEVELOPMENT, WE DEVELOPED A FIRST-IN-CLASS LIGAND-INDEPENDENT TREM-1 INHIBITORY PEPTIDE GF9 THAT IS WELL-TOLERATED AND CAN BE FORMULATED INTO SIGNABLOK'S LONG HALF-LIFE MACROPHAGE-SPECIFIC LIPOPEPTIDE COMPLEXES (LPC) TO IMPROVE ITS HALF-LIFE AND TARGETING TO THE INFLAMMATION AREAS. THE MAJOR GOAL OF THE PHASE I STUDY IS TO SHOW THAT TREM-1 BLOCKADE BY GF9-LPC ALLEVIATES THE DISEASE IN A BLEOMYCIN (BLM)-INDUCED MOUSE MODEL OF SCLERODERMA. PHASE I SPECIFIC AIMS ARE TO: 1) OPTIMIZE TREM-1 INHIBITORY COMPOSITIONS FOR THEIR FUNCTIONALITY IN VITRO AND PHARMACOKINETICS IN VIVO AND SELECT THE LEAD, 2) TEST TWO DOSES OF THE LEAD SELECTED IN A BLM-INDUCED MOUSE MODEL OF SCLERODERMA. WE WILL GENERATE, OPTIMIZE AND SELECT THE LEAD BASED UPON ITS FUNCTIONALITY IN VITRO AND ITS PK PROFILE IN VIVO. WE WILL TEST TWO DOSES OF THE LEAD FOR ITS ABILITY TO PREVENT AND TREAT LUNG, HEART, MUSCLE AND SKIN FIBROSIS IN A MOUSE MODEL OF MULTIORGAN FIBROSIS IN VIVO. HISTOLOGY/IHC STUDIES WILL BE PERFORMED. SERUM AND TISSUE MCP-1, CSF-1, VEGF, TGFSS, TNFA, IL-6, AND IL-1SS WILL BE ANALYZED. IT IS ANTICIPATED THAT THE PHASE I STUDY WILL IDENTIFY A NOVEL, FIRST-IN-CLASS, WELL TOLERABLE AGENT AS A POWERFUL PLATFORM FOR DEVELOPMENT OF AN EFFECTIVE AND WELL-TOLERABLE SYSTEMIC SCLERODERMA THERAPY, THEREBY IMPROVING TREATMENT AND SURVIVAL OF PATIENTS. ITS ANTICIPATED SAFETY IS SUPPORTED BY GOOD TOLERABILITY OF SIGNABLOK'S GF9-BASED FORMULATIONS BY LONG TERM-TREATED MICE. PROTOTYPES OF SIGNABLOK'S LPC ARE WELL TOLERATED IN HUMANS. TREM-1 BLOCKADE BY SIGNABLOK COMPETITOR'S INHIBITORY PEPTIDE LR12 (INOTREM, FRANCE) WAS SAFE IN HEALTHY AND SEPTIC SUBJECTS. IF SUCCESSFUL, PHASE I WILL BE FOLLOWED IN PHASE II BY TOXICOLOGY, ADME, PHARMACOLOGY AND CMC STUDIES, FILING AN IND AND SUBSEQUENT EVALUATION IN HUMANS.
$0
3/8/21
Not listed
TREM-1 INHIBITOR FOR THE TREATMENT OF SCLERODERMA - PROJECT SUMMARY/ABSTRACT SCLERODERMA THAT INCLUDES LOCALIZED SCLERODERMA (LS) AND SYSTEMIC SCLEROSIS (SSC) IS A RARE BUT DEVASTATING AUTOIMMUNE DISORDER. CURRENT THERAPIES ALL HAVE SIDE EFFECTS, ARE LIMITED AND ASSOCIATE WITH 10 YEAR SURVIVAL OF 55%, SHOWING THE NEED FOR NOVEL APPROACHES. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A NEW MECHANISM-BASED, EFFICIENT AND WELL TOLERABLE SCLERODERMA THERAPY. TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 (TREM-1), AN INFLAMMATION AMPLIFIER, CONTRIBUTES TO THE DEVELOPMENT OF FIBROSIS IN SSC. IN PATIENTS, NUMBER OF ACTIVATED MACROPHAGES IN THE FIBROTIC AREAS IS INCREASED AND ASSOCIATES WITH FIBROSIS SEVERITY. ACTIVATION OF TREM-1 LEADS TO OVERPRODUCTION OF MCP- 1/CCL2 AND M-CSF/CSF-1, RESULTING IN MACROPHAGE RECRUITMENT TO AN INJURED AREA AND THE SCLEROTIC LESION FORMATION IN RATS WITH SCLERODERMA. IN ANIMAL MODELS, TREM-1 BLOCKADE INHIBITS INFLAMMATION AND AMELIORATES A VARIETY OF AUTOIMMUNE DISEASES. THE HYPOTHESIS OF THE "PROOF-OF-CONCEPT" PHASE I IS THAT TREM-1 BLOCKADE CAN PREVENT AND TREAT SCLERODERMA. CURRENT TREM-1 INHIBITORS ALL ATTEMPT TO BLOCK BINDING OF TREM-1 TO ITS STILL UNCERTAIN LIGAND(S). TO MINIMIZE RISK OF FAILURE IN CLINICAL DEVELOPMENT, WE DEVELOPED A FIRST-IN-CLASS LIGAND-INDEPENDENT TREM-1 INHIBITORY PEPTIDE GF9 THAT IS WELL-TOLERATED AND CAN BE FORMULATED INTO SIGNABLOK'S LONG HALF-LIFE MACROPHAGE-SPECIFIC LIPOPEPTIDE COMPLEXES (LPC) TO IMPROVE ITS HALF-LIFE AND TARGETING TO THE INFLAMMATION AREAS. THE MAJOR GOAL OF THE PHASE I STUDY IS TO SHOW THAT TREM-1 BLOCKADE BY GF9-LPC ALLEVIATES THE DISEASE IN A BLEOMYCIN (BLM)-INDUCED MOUSE MODEL OF SCLERODERMA. PHASE I SPECIFIC AIMS ARE TO: 1) OPTIMIZE TREM-1 INHIBITORY COMPOSITIONS FOR THEIR FUNCTIONALITY IN VITRO AND PHARMACOKINETICS IN VIVO AND SELECT THE LEAD, 2) TEST TWO DOSES OF THE LEAD SELECTED IN A BLM-INDUCED MOUSE MODEL OF SCLERODERMA. WE WILL GENERATE, OPTIMIZE AND SELECT THE LEAD BASED UPON ITS FUNCTIONALITY IN VITRO AND ITS PK PROFILE IN VIVO. WE WILL TEST TWO DOSES OF THE LEAD FOR ITS ABILITY TO PREVENT AND TREAT LUNG, HEART, MUSCLE AND SKIN FIBROSIS IN A MOUSE MODEL OF MULTIORGAN FIBROSIS IN VIVO. HISTOLOGY/IHC STUDIES WILL BE PERFORMED. SERUM AND TISSUE MCP-1, CSF-1, VEGF, TGFSS, TNFA, IL-6, AND IL-1SS WILL BE ANALYZED. IT IS ANTICIPATED THAT THE PHASE I STUDY WILL IDENTIFY A NOVEL, FIRST-IN-CLASS, WELL TOLERABLE AGENT AS A POWERFUL PLATFORM FOR DEVELOPMENT OF AN EFFECTIVE AND WELL-TOLERABLE SYSTEMIC SCLERODERMA THERAPY, THEREBY IMPROVING TREATMENT AND SURVIVAL OF PATIENTS. ITS ANTICIPATED SAFETY IS SUPPORTED BY GOOD TOLERABILITY OF SIGNABLOK'S GF9-BASED FORMULATIONS BY LONG TERM-TREATED MICE. PROTOTYPES OF SIGNABLOK'S LPC ARE WELL TOLERATED IN HUMANS. TREM-1 BLOCKADE BY SIGNABLOK COMPETITOR'S INHIBITORY PEPTIDE LR12 (INOTREM, FRANCE) WAS SAFE IN HEALTHY AND SEPTIC SUBJECTS. IF SUCCESSFUL, PHASE I WILL BE FOLLOWED IN PHASE II BY TOXICOLOGY, ADME, PHARMACOLOGY AND CMC STUDIES, FILING AN IND AND SUBSEQUENT EVALUATION IN HUMANS.
$0
3/8/21
Not listed
TREM-1 INHIBITOR FOR THE TREATMENT OF SCLERODERMA
$249.6k
9/10/20